Updated

Lenacapavir, an innovative twice-yearly injection, has been hailed as a potential breakthrough in HIV prevention capable of transforming disease prevention efforts globally. However, the development raises urgent questions about equitable access and affordability, as the drug will not be available to all populations that could benefit from it. The breakthrough highlights the persistent gap between medical innovation and global health equity.